T1	Pharmacological_substance 75 85	cytarabine
N1000 	Reference T1 MeSH:D003561	cytarabine
T2	Disorder 100 128	acute lymphoblastic leukemia
N1 	Reference T2 UMLS:C0023449	acute lymphoblastic leukemia
T3	Disorder 266 282	painful erythema
T4	Pharmacological_substance 355 365	cytarabine
N1001 	Reference T4 MeSH:D003561	cytarabine
T5	Pharmacological_substance 397 407	cytarabine
N1002 	Reference T5 MeSH:D003561	cytarabine
T6	Disorder 530 546	bullous eruption
N2 	Reference T6 UMLS:C0235818	bullous eruption
T7	Pharmacological_substance 589 599	cytarabine
N1003 	Reference T7 MeSH:D003561	cytarabine
T8	Disorder 621 650	acute lymphoblastic leukaemia
N3 	Reference T8 UMLS:C0023449	acute lymphoblastic leukaemia
T9	Pharmacological_substance 751 761	cytarabine
N1004 	Reference T9 MeSH:D003561	cytarabine
T11	Disorder 939 964	haematologic malignancies
N4 	Reference T11 UMLS:C0376545	haematologic malignancies
T12	Disorder 131 165	Palmar-plantar erythrodysaesthesia
T13	Disorder 167 170	PPE
T16	Disorder 341 344	PPE
T17	Disorder 490 493	PPE
T14	Disorder 786 789	PPE
T15	Disorder 20 54	palmar-plantar erythrodysaesthesia
T20	Pharmacological_substance 213 235	cytotoxic chemotherapy
T27	Negation_cue 371 374	not
T28	Subject 434 441	patient
T31	Subject 765 773	patients
T32	Speculation_cue 823 832	potential
T35	Disorder 833 841	toxicity
N5 	Reference T35 UMLS:C0600688	toxicity
T36	Pharmacological_substance 845 855	this agent
T37	Speculation_cue 326 335	suggested
